KATI GRIMES: Open Payments
NPI 1821440959 · GENESEO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$809 in 45 payments from 11 companies in 2025. Trend: 2023 $1,159 · 2024 $1,175 · 2025 $809
Food & beverage: $809
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $210 |
| ABBVIE INC. | 4 | $101 |
| Novo Nordisk Inc | 6 | $94 |
| PFIZER INC. | 6 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Exact Sciences Corporation | 3 | $45 |
| Lilly USA, LLC | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 4 | $29 |
| Almatica Pharma LLC | 1 | $22 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Wegovy, NURTEC ODT, FARXIGA, AIRSUPRA, ELIQUIS.
Industry payments across IL — which companies pay providers there.
